Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Different cancers remain major global health challenges due to their diverse biological behaviors and significant treatment hurdles. The aging of populations and lifestyle factors increase cancer occurrence and place increasing pressure on healthcare systems. Despite continuous advancements, many cancers remain fatal due to late-stage diagnosis, tumor heterogeneity, and drug resistance, thus necessitating urgent development of innovative treatment solutions. Therapeutic nucleic acids, a new class of biological drugs, offer a promising approach to overcoming these challenges. The recent Nucleic Acids and Nanobiosystems in Cancer Theranostics (NANCT) conference brought together internationally recognized experts from 15 countries to discuss cutting-edge research, spanning from oncolytic viruses to anticancer RNA nanoparticles and other emerging nanotechnologies. This review captures key insights and developments, emphasizing the need for interdisciplinary translation of scientific advancements into clinical practice and shaping the future of personalized cancer treatments for improved therapeutic outcomes.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12140469 | PMC |
| http://dx.doi.org/10.1080/17435889.2025.2501919 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Programmable immunoprobiotics orchestrate antitumor immune response with Pin1 inhibition for pancreatic cancer treatment.
Proc Natl Acad Sci U S A
August 2025
Pharmaceutical Sciences Division, School of Pharmacy, University of Wisconsin-Madison, Madison, WI 53705.
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive cancer with limited treatment options due to its desmoplastic and immunosuppressive tumor microenvironment (TME), which impedes drug delivery and limits T cell infiltration. Immune checkpoint blockade (ICB) has shown poor efficacy in PDAC, partly due to the desmoplastic stroma and low immunogenicity. Peptidyl-prolyl cis/trans isomerase NIMA-interacting 1 (Pin1) promotes both fibrosis and immune evasion, making it a compelling target for TME remodeling.
View Article and Find Full Text PDFBiomaterial scaffolds for therapeutic immune cell engineering and delivery.
J Control Release
July 2025
Pharmaceutical Sciences Division, School of Pharmacy, University ofWisconsin Madison, Madison, WI 53705, USA; Carbone Cancer Center, School of Medicine and Public Health, University ofWisconsin-Madison, Madison, WI 53705, USA; Wisconsin Center for NanoBioSystems, School of Pharmacy, University of
Cell-based therapeutics represent an emerging treatment modality for a variety of ailments and diseases. Adoptive cell therapies, including T cell therapies have demonstrated remarkable success in the treatment of cancers. With the demonstrated efficacy and successful navigation of regulatory hurdles by multiple cell therapies, researchers are looking to expand their application and increase their efficacy.
View Article and Find Full Text PDFEndogenous tyrosinase-catalyzed therapeutics.
Nat Commun
July 2025
Pharmaceutical Sciences Division, School of Pharmacy, University of Wisconsin-Madison, Madison, WI, USA.
Tyrosinase (TYR) catalyzes the two initial steps of melanin synthesis from tyrosine in various organisms. However, overproduction, accumulation, and abnormal reduction of melanin can lead to severe diseases, particularly skin diseases, which makes tyrosinase a significant endogenous target in developing therapeutics to treat melanin-associated disorders. Herein, we devise a TYR-based in situ catalytic platform that can generate drugs intracellularly through an endogenous copper-catalyzed azide-alkyne cycloaddition (CuAAC) reaction.
View Article and Find Full Text PDFEnhancing breast cancer diagnosis through machine learning algorithms.
Sci Rep
July 2025
Nano Bio Electronic Devices Lab, School of Electrical and Computer Engineering, College of Engineering, University of Tehran, Tehran, Iran.
Among the most important health concerns in the world, and the number one cause of death in women, is breast cancer. Bearing in mind that there are more than 100 types of cancer, each presenting different symptoms, its early detection is indeed a big challenge. The prevalence of breast cancer indicates the prudent need for effective diagnostic and prognostic approaches.
View Article and Find Full Text PDFThe Role of Dendrimers in Improving Antibody and Peptide Biologics for Cancer Treatment.
Langmuir
July 2025
Pharmaceutical Sciences Division, School of Pharmacy, University of Wisconsin-Madison, Madison, Wisconsin 53705, United States.
Dendrimer-based platforms, including dendrimer-antibody conjugates (DACs) and dendrimer-peptide conjugates (DPCs), are emerging as promising tools in cancer therapy due to their potential to enhance tumor specificity and therapeutic efficacy. These nanoscale macromolecules leverage multivalency of their conjugated biologics to simultaneously bind to multiple target proteins that are overexpressed on the surface of cancer cells, thereby substantially enhancing their binding kinetics and in turn overall selectivity and therapeutics efficacy. Furthermore, DACs and DPCs can be further engineered through surface modifications, such as PEGylation, which improve biocompatibility and extend systemic circulation times.
View Article and Find Full Text PDF